ClinicalTrials.gg
CompletedNCT03554304Updated Jun 13, 2018

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

A Phase 1 interventional study of WCK 5222 and IV placebo matched to WCK 5222 / Moxifloxacin IV solution in QT/QTc Interval in Healthy Volunteers, sponsored by Wockhardt. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-13.

Sponsored by Wockhardt · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2017, 9 years 5 months ago, and no results have been posted to the registry.
  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2017, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

02

Conditions studied

  • QT/QTc Interval in Healthy Volunteers
03

In context

Lead sponsor

Wockhardt is the lead sponsor of 39 studies on the registry; 3 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 to ≤33 kg/m2, inclusive.
  2. Stable health based on a medical history without any major pathology/surgery in the 6 months

Exclusion criteria

Exclusion Criteria:

  1. An uninterpretable or abnormal screening (ECG) indicating a second- or third-degree atrioventricular block
  2. History of risk factors for torsades de pointes, including unexplained syncope, known long syndrome, heart failure, myocardial infarction, angina, or abnormal laboratory assessments including hypokalemia, hypocalcemia, or hypomagnesemia.
  3. A sustained supine systolic blood pressure >150 mm Hg or \<90 mm Hg or a supine diastolic blood pressure >95 mm Hg or \<50 mm Hg at Screening or Check-in (Day -1).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    WCK 5222

    WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)

    Drug: WCK 5222 · Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution

  • Placebo comparator
    Placebo (IV placebo matched toWCK 5222IV solution)

    placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution

    Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution

  • Active comparator
    Moxifloxacin 400-mg

    positive control

    Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution · Drug: Moxifloxacin 400-mg

Interventions

  • FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)

  • DrugIV placebo matched to WCK 5222 / Moxifloxacin IV solution

    Placebo (IV placebo matched to FEP-ZID IV solution) and 1 placebo capsule matched to moxifloxacin overencapsulated tablet

    Also known as: Placebo capsule matched to moxifloxacin

  • DrugMoxifloxacin 400-mg

    Moxifloxacin 400-mg positive control (overencapsulated tablet)

06

What researchers measure

Primary outcomes

  1. Incidence of delay in cardiac repolarization induced by WCK 5222

    as shown by analysis of the QT interval.

    Time frame: 0-4 days

Secondary outcomes

  1. Incidence of adverse events to assess tolerability at the supratherapeutic dose to be used in the thorough QT evaluation

    Tolerability will be assessed by review of number of AEs

    Time frame: 0-4 days

  2. Incidence of AEs to assess the safety of high doses of single-dose administration of FEP-ZID

    Safety will be assessed by review of adverse events (AEs), ECGs, and clinical laboratory safety test results

    Time frame: 0-4 days

07

Study locations

1 site
  • Spaulding Clinical Research
    West Bend, Wisconsin 53095, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Jun 2017, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2018
First posted
Jun 13, 2018
StartActual
Feb 9, 2017
Primary completionActual
Jun 5, 2017
CompletionActual
Oct 6, 2017
Last update
Jun 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03554304
Lead sponsor
Wockhardt
Responsible party
Sponsor
First posted
Jun 13, 2018
Start date
Feb 9, 2017
Primary completion
Jun 5, 2017
Completion
Oct 6, 2017
Last update
Jun 13, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cefepime-zidebactam

Start the discussion